Menu

Stock Quote - HSM-T

*Delayed quote courtesy of Google.

Stock Quote - HSDT

*Delayed quote courtesy of Google.

About Helius

Helius had its beginnings in a lab at the University of Wisconsin-Madison. Now, we’re a publicly traded company on the Toronto Stock Exchange in Canada and the NASDAQ in the United States, partnering with top organizations to pioneer unique, noninvasive platform technologies that support neurological wellness.

Our History at a Glance

Early 1990s: The Tactile Communication and Neurorehabilitation Laboratory (TCNL) was founded at the University of Wisconsin-Madison.

Late 2000s: TCNL developed and built the Portable Neuromodulation Stimulator™ (PoNS) device and principals formed Advanced NeuroRehabilitation, LLC (ANR).

2013: ANR and MPJ Healthcare formed NeuroHabilitation Corporation, which signed a Collaborative Research and Development Agreement (CRADA) with the US Department of Defense.

2014: Helius Medical Technologies (Helius) acquired NeuroHabilitation in a reverse merger and became a publicly traded company on the Canadian Securities Exchange.

The Early Days

In the early 1990s, the late professor Dr. Paul Bach-y-Rita founded the Tactile Communication and Neurorehabilitation Laboratory (TCNL) at the University of Wisconsin-Madison, where he was joined by Kurt Kaczmarek, Mitchell Tyler and Yuri Danilov. This team pioneered work in neuroplasticity and expanded research into the development of sensory substitution devices. Their Tongue Display Unit, the first instrumentation platform for tongue tactile display research, is now used by numerous US and international clinical collaborators.

Advances in Neuromodulation

By the late 2000s, TCNL had analyzed the first data to support translingual neurostimulation (TLNS) and found that whole-tongue electrotactile stimulation without sensory substitution significantly improves the effectiveness of therapeutic exercises in people with vestibular disorders.

Becoming HMT

In 2013, ANR and MPJ Healthcare formed a joint venture called NeuroHabilitation Corporation to develop and commercialize the PoNS device. NeuroHabilitation signed a Collaborative Research and Development Agreement (CRADA) with the US Department of Defense to develop and manage clinical and regulatory activities for the PoNS device and CN-NINM technologies. Late in the year, Philippe Deschamps was named CEO of NeuroHabilitation Corporation.